Antibody-drug conjugates targeting CD45 plus Janus kinase inhibitors effectively condition for allogeneic hematopoietic stem cell transplantation
S. P. Persaud, J. K. Ritchey, J. Choi, P. G. Ruminski, M. L. Cooper, M. P. Rettig, J. F. DiPersio
This study shows that combining CD45-targeted ADCs with baricitinib enables effective allogeneic HSCT with high donor chimerism and reduced graft-versus-host disease.
bioRxiv · Oct 2, 2020Immunology